Quince Therapeutics (NASDAQ:QNCX) Releases Earnings Results, Misses Estimates By $0.09 EPS

Quince Therapeutics (NASDAQ:QNCX) announced its quarterly earnings data on Monday. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.09), Zacks reports. The firm had revenue of $0.17 million during the quarter.

Quince Therapeutics Stock Up 1.4 %

QNCX opened at $1.40 on Tuesday. The stock’s fifty day simple moving average is $1.49 and its 200 day simple moving average is $1.44. Quince Therapeutics has a 1-year low of $0.51 and a 1-year high of $2.45. The stock has a market cap of $61.60 million, a PE ratio of -1.13 and a beta of 0.71. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Oppenheimer began coverage on Quince Therapeutics in a research report on Monday. They set an “outperform” rating and a $10.00 price target for the company. Brookline Capital Management began coverage on Quince Therapeutics in a report on Wednesday, December 18th. They issued a “buy” rating and a $9.00 price objective for the company. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $12.00 price target on shares of Quince Therapeutics in a research report on Wednesday, February 5th. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $9.60.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.